Key Drivers
- Margin Strength
- Leverage Watch
- Premium Valuation
AIAI Summary
ILMN should now be viewed less as a turnaround and more as a cash-generative sequencing platform with optionality in clinical, oncology, MRD, and software, but with much of that better profile already priced in, investors should focus on whether new launches convert into durable demand amid weak China and intensifying Roche competition.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Leverage Watch
- •Premium Valuation
ILMN combines strong margins, cash generation, and returns with solid liquidity, but meaningful leverage, an intangible-heavy balance sheet, and a premium valuation cap upside.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Choppy rally
- •Extended setup
ILMN has trended higher over the last month with persistent higher highs and higher lows, but the rally is choppy and extended, leaving $181.10 then $175-$176 as key support and $190 as the next resistance hurdle.
Sharp pullbacks during the advance created a choppy, volatile run
Sentiment & News
Key News Insights:
- •Product expansion
- •NovaSeq demand
- •Roche competition
Illumina's product expansion, board addition, and strong NovaSeq X demand support a constructive outlook, but China weakness, cost pressures, and rising Roche competition remain key risks.
The news flow is broadly supportive for sentiment and growth momentum, though near-term upside may be tempered by operational headwinds and intensifying competition
Similar Companies in Healthcare
Other companies in the same sector with AI ratings